|
1
|
Brandse JF, van den Brink GR, Wildenberg
ME, van der Kleij D, Rispens T, Jansen JM, Mathôt RA, Ponsioen CY,
Löwenberg M and D'Haens GR: Loss of infliximab into feces is
associated with lack of response to therapy in patients with severe
ulcerative colitis. Gastroenterology. 149:350–355.e2. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boschetti G, Nancey S, Moussata D,
Stefanescu C, Roblin X, Chauvenet M, Stroeymeyt K, Bouhnik Y and
Flourié B: Tacrolimus induction followed by maintenance monotherapy
is useful in selected patients with moderate-to-severe ulcerative
colitis refractory to prior treatment. Dig Liver Dis. 46:875–880.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okuyama Y, Andoh A, Nishishita M, Fukunaga
K, Kamikozuru K, Yokoyama Y, Ueno Y, Tanaka S, Kuge H, Yoshikawa S,
et al: Multicenter prospective study for clinical and endoscopic
efficacies of leukocytapheresis therapy in patients with ulcerative
colitis. Scand J Gastroenterol. 48:412–418. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cleynen I, Boucher G, Jostins L, Schumm
LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S,
et al: Inherited determinants of Crohn's disease and ulcerative
colitis phenotypes: A genetic association study. Lancet.
387:156–167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heikens JT, De Vries J, De Jong DJ, den
Oudsten BL, Hopman W, Groenewoud JM, van der Kolk MB, Gooszen HG
and van Laarhoven CJ: Evaluation of long-term function,
complications, quality of life and health status after restorative
proctocolectomy with ileo neo rectal and with ileal pouch anal
anastomosis for ulcerative colitis. Colorectal Dis. 15:e323–e329.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adedokun OJ, Xu Z, Padgett L, Blank M,
Johanns J, Griffiths A, Ford J, Zhou H, Guzzo C, Davis HM and Hyams
J: Pharmacokinetics of infliximab in children with
moderate-to-severe ulcerative colitis: Results from a randomized,
multicenter, open-label, phase 3 study. Inflamm Bowel Dis.
19:2753–2762. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guardiola J, Lobatón T, Rodríguez-Alonso
L, Ruiz-Cerulla A, Arajol C, Loayza C, Sanjuan X, Sánchez E and
Rodríguez-Moranta F: Fecal level of calprotectin identifies
histologic inflammation in patients with ulcerative colitis in
clinical and endoscopic remission. Clin Gastroenterol Hepatol.
12:1865–1870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takeda Y, Nakase H, Namba K, Inoue S, Ueno
S, Uza N and Chiba T: Upregulation of T-bet and tight junction
molecules by Bifidobactrium longum improves colonic inflammation of
ulcerative colitis. Inflamm Bowel Dis. 15:1617–1618. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laake KO, Line PD, Aabakken L, Løtveit T,
Bakka A, Eide J, Roseth A, Grzyb K, Bjørneklett A and Vatn MH:
Assessment of mucosal inflammation and circulation in response to
probiotics in patients operated with ileal pouch anal anastomosis
for ulcerative colitis. Scand J Gastroenterol. 38:409–414. 2003.
View Article : Google Scholar
|
|
10
|
Yang SK, Jung HY, Kang GH, Kim YM, Myung
SJ, Shim KN, Hong WS and Min YI: Appendiceal orifice inflammation
as a skip lesion in ulcerative colitis: An analysis in relation to
medical therapy and disease extent. Gastrointest Endosc.
49:743–747. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mawdsley JE, Jenkins DG, Macey MG,
Langmead L and Rampton DS: The effect of hypnosis on systemic and
rectal mucosal measures of inflammation in ulcerative colitis. Am J
Gastroenterol. 103:1460–1469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mannon PJ, Hornung RL, Yang Z, Yi C,
Groden C, Friend J, Yao M, Strober W and Fuss IJ: Suppression of
inflammation in ulcerative colitis by interferon-b-1a is
accompanied by inhibition of IL-13 production. Gut. 60:449–455.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wilson MJ, Lindgren BR and Sinha AA: The
effect of dietary supplementation with limonene or myo-inositol on
the induction of neoplasia and matrix metalloproteinase and
plasminogen activator activities in accessory sex organs of male
Lobund-Wistar rats. Exp Mol Pathol. 85:83–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marmulla R and Harder J: Microbial
monoterpene transformations-a review. Front Microbiol. 5:3462014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rehman MU, Tahir M, Khan AQ, Khan R,
Hamiza Oday-O, Lateef A, Hassan SK, Rashid S, Ali N, Zeeshan M and
Sultana S: D-limonene suppresses doxorubicin-induced oxidative
stress and inflammation via repression of COX-2, iNOS, and NFκB in
kidneys of Wistar rats. Exp Biol Med (Maywood). 239:465–476. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoon WJ, Lee NH and Hyun CG: Limonene
suppresses lipopolysaccharide-induced production of nitric oxide,
prostaglandin E2, and pro-inflammatory cytokines in RAW 2647
macrophages. J Oleo Sci. 59:415–421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chaudhary SC, Siddiqui MS, Athar M and
Alam MS: D-Limonene modulates inflammation, oxidative stress and
Ras-ERK pathway to inhibit murine skin tumorigenesis. Hum Exp
Toxicol. 31:798–811. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mao JW, He XM, Tang HY and Wang YD:
Protective role of metalloproteinase inhibitor (AE-941) on
ulcerative colitis in rats. World J Gastroenterol. 18:7063–7069.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Assche G, Manguso F, Zibellini M,
Cabriada N, uño JL, Goldis A, Tkachenko E, Varoli G, Kleczkowski D,
Annese V, D'Heygere F, et al: Oral prolonged release beclomethasone
dipropionate and prednisone in the treatment of active ulcerative
colitis: Results from a double-blind, randomized, parallel group
study. Am J Gastroenterol. 110:708–715. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trifan A, Stanciu C, Stoica O, Girleanu I
and Cojocariu C: Impact of Clostridium difficile infection on
inflammatory bowel disease outcome: A review. World J
Gastroenterol. 20:11736–11742. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hirota R, Nakamura H, Bhatti SA, Ngatu NR,
Muzembo BA, Dumavibhat N, Eitoku M, Sawamura M and Suganuma N:
Limonene inhalation reduces allergic airway inflammation in
Dermatophagoides farinae-treated mice. Inhal Toxicol. 24:373–381.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jorgensen JR and Mortensen PB: Influence
of feces from patients with ulcerative colitis on butyrate
oxidation in rat colonocytes. Dig Dis Sci. 44:2099–2109. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alagozlu H, Gorgul A, Bilgihan A, Tuncer C
and Unal S: Increased plasma levels of advanced oxidation protein
products (AOPP) as a marker for oxidative stress in patients with
active ulcerative colitis. Clin Res Hepatol Gastroenterol.
37:80–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Keshavarzian A, Banan A, Farhadi A,
Komanduri S, Mutlu E, Zhang Y and Fields JZ: Increases in free
radicals and cytoskeletal protein oxidation and nitration in the
colon of patients with inflammatory bowel disease. Gut. 52:720–728.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roediger WE: Review article: Nitric oxide
from dysbiotic bacterial respiration of nitrate in the pathogenesis
and as a target for therapy of ulcerative colitis. Aliment
Pharmacol Ther. 27:531–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rizk M, Ibrahim N and El-Rigal N:
Comparative in vivo antioxidant levels in Schistosoma mansoni
infected mice treated with praziquantel or the essential oil of
Melaleuca armillaris leaves. Pak J Biol Sci. 15:971–978. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang CX, Guo LK and Guo XF: Interaction
between the polymorphisms of cyclooxygenase-2-1195G/A,
MnSOD9Ala/val genes and the high-fat diets and its correlation with
ulcerative colitis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 37:37–43.
2015.PubMed/NCBI
|
|
29
|
Hussein I Abdallah Hajj, Freund JN,
Reimund JM, Shams A, Yamine M, Leone A and Jurjus AR:
Enteropathogenic e.coli sustains iodoacetamide-induced ulcerative
colitis-like colitis in rats: Modulation of IL-1β, IL-6, TNF-α,
COX-2, and apoptosisi. J Biol Regul Homeost Agents. 26:515–526.
2012.PubMed/NCBI
|
|
30
|
Fratila OC and Iliaş TI: COX-2 and Ki-67
immunohistochemical markers in the assessment of long-standing
ulcerative colitis associated dysplasia. Rom J Morphol Embryol.
54:143–149. 2013.PubMed/NCBI
|
|
31
|
Roulis M, Nikolaou C, Kotsaki E, Kaffe E,
Karagianni N, Koliaraki V, Salpea K, Ragoussis J, Aidinis V,
Martini E, et al: Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2
pathway links innate sensing to epithelial homeostasis. Proc Natl
Acad Sci USA. 111:E4658–E4667. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tammali R, Ramana KV and Srivastava SK:
Aldose reductase regulates TNF-alpha-induced PGE2 production in
human colon cancer cells. Cancer Lett. 252:299–306. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guan F, Wang H, Shan Y, Chen Y, Wang M,
Wang Q, Yin M, Zhao Y, Feng X and Zhang J: Inhibition of COX-2 and
PGE in LPS-stimulated RAW264.7 cells by lonimacranthoide VI, a
chlorogenic acid ester saponin. Biomed Rep. 2:760–764.
2014.PubMed/NCBI
|
|
34
|
Li C, Iness A, Yoon J, Grider JR, Murthy
KS, Kellum JM and Kuemmerle JF: Noncanonical STAT3 activation
regulates excess TGF-β1 and collagen I expression in muscle of
stricturing Crohn's disease. J Immunol. 194:3422–3431. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fleissner D, Frede A, Knott M, Knuschke T,
Geffers R, Hansen W, Dobos G, Langhorst J, Buer J and Westendorf
AM: Generation and function of immunosuppressive human and murine
CD8+ T cells by transforming growth factor-β and retinoic acid.
Immunology. 134:82–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Setia S, Nehru B and Sanyal SN:
Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative
colitis-associated colon cancer. Biomed Pharmacother. 68:1023–1029.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dambacher J, Beigel F, Seiderer J, Haller
D, Göke B, Auernhammer CJ and Brand S: Interleukin 31 mediates MAP
kinase and STAT1/3 activation in intestinal epithelial cells and
its expression is upregulated in inflammatory bowel disease. Gut.
56:1257–1265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lv Q, Qiao SM, Xia Y, Shi C, Xia YF, Chou
GX, Wang ZT, Dai Y and Wei ZF: Norisoboldine ameliorates
DSS-induced ulcerative colitis in mice through induction of
regulatory T cells in colons. Int Immunopharmacol. 29:787–797.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rezaie A, Khalaj S, Shabihkhani M, Nikfar
S, Zamani MJ, Mohammadirad A, Daryani NE and Abdollahi M: Study on
the correlations among disease activity index and salivary
transforming growth factor-beta 1 and nitric oxide in ulcerative
colitis patients. Ann N Y Acad Sci. 1095:305–314. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rufino AT, Ribeiro M, Sousa C, Judas F,
Salgueiro L, Cavaleiro C and Mendes AF: Evaluation of the
anti-inflammatory, anti-catabolic and pro-anabolic effects of
E-caryophyllene, myrcene and limonene in a cell model of
osteoarthritis. Eur J Pharmacol. 750:141–150. 2015. View Article : Google Scholar : PubMed/NCBI
|